Uveal melanoma

Common Name(s)

Uveal melanoma

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Uveal melanoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Uveal melanoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Uveal melanoma" returned 295 free, full-text research articles on human participants. First 3 results:

Epigallocatechingallate inhibits migration of human uveal melanoma cells via downregulation of matrix metalloproteinase-2 activity and ERK1/2 pathway.
 

Author(s): Chi-Wu Chang, Yi-Hsien Hsieh, Wei-En Yang, Shun-Fa Yang, Yueqin Chen, Dan-Ning Hu

Journal: Biomed Res Int. 2014 ;2014():141582.

 

The effects of epigallocatechingallate (EGCG) on the migration and expression of MMP-2 of uveal melanoma cells have not been reported. We studied this effect and relevant signaling pathways in a human uveal melanoma cell line (M17). MTT study found that EGCG did not affect the cell ...

Last Updated: 3 Sep 2014

Go To URL
Metabolic activity of primary uveal melanoma on PET/CT scan and its relationship with monosomy 3 and other prognostic factors.
 

Author(s): Vasilios P Papastefanou, Shahriar Islam, Teresa Szyszko, Marianne Grantham, Mandeep S Sagoo, Victoria M L Cohen

Journal: Br J Ophthalmol. 2014 Dec;98(12):1659-65.

 

To correlate the metabolic activity of primary uveal melanoma on positron emission tomography (PET)/CT scan with known clinical and pathological prognostic factors.

Last Updated: 15 Nov 2014

Go To URL
Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.
 

Author(s): Kalijn F Bol, Hanneke W Mensink, Erik H J G Aarntzen, Gerty Schreibelt, Jan E E Keunen, Pierre G Coulie, Annelies de Klein, Cornelis J A Punt, Dion Paridaens, Carl G Figdor, I Jolanda M de Vries

Journal: Am. J. Ophthalmol.. 2014 Nov;158(5):939-47.

 

To assess the safety and efficacy of dendritic cell vaccination in metastatic uveal melanoma.

Last Updated: 2 Dec 2014

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Uveal melanoma" returned 17 free, full-text review articles on human participants. First 3 results:

Recent developments in prognostic and predictive testing in uveal melanoma.
 

Author(s): Matthew G Field, J William Harbour

Journal: Curr Opin Ophthalmol. 2014 May;25(3):234-9.

 

To provide an update on the rapidly evolving methods for assessing prognosis and predicting response to targeted molecular therapy in uveal melanoma.

Last Updated: 9 Apr 2014

Go To URL
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives.
 

Author(s): Kristina Buder, Anja Gesierich, Götz Gelbrich, Matthias Goebeler

Journal: Cancer Med. 2013 Oct;2(5):674-86.

 

Up to 50% of patients with uveal melanoma develop metastatic disease with poor prognosis. Regional, mainly liver-directed, therapies may induce limited tumor responses but do not improve overall survival. Response rates of metastatic uveal melanoma (MUM) to systemic chemotherapy are ...

Last Updated: 9 Jan 2014

Go To URL
The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma.
 

Author(s): ,

Journal: Brachytherapy. ;13(1):1-14.

 

To present the American Brachytherapy Society (ABS) guidelines for plaque brachytherapy of choroidal melanoma and retinoblastoma.

Last Updated: 20 Jan 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

There are currently no related results available in Genetic Testing Registry.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases
 

Status: Recruiting

Condition Summary: Iris Melanoma; Medium/Large Size Posterior Uveal Melanoma; Stage IIA Uveal Melanoma; Stage IIB Uveal Melanoma; Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma

 

Last Updated: 8 Jan 2015

Go to URL
Pembrolizumab in Treating Patients With Advanced Uveal Melanoma
 

Status: Not yet recruiting

Condition Summary: Stage IIIA Uveal Melanoma; Stage IIIB Uveal Melanoma; Stage IIIC Uveal Melanoma; Stage IV Uveal Melanoma

 

Last Updated: 10 Apr 2015

Go to URL
Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma
 

Status: Not yet recruiting

Condition Summary: Recurrent Uveal Melanoma; Stage IV Uveal Melanoma

 

Last Updated: 27 Jul 2015

Go to URL